Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Trials › GRADUAL-1 (NCT06728124)

GRADUAL-1 (NCT06728124)

Bofanglutide (GZR18) · obesity

Data cut 12 November 2026 · page built 16 November 2026

Design

Molecule(s)
Bofanglutide (GZR18)
Population
obesity
Official title
A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Obese/Overweight Subjects
Sponsor
Gan & Lee Pharmaceuticals.
Phase
3
Registry status
completed · 2024-12 → 2026-03
Participants
640
Duration
52 weeks
Registry
NCT06728124

Results by arm

ArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
24 mg Q2Wobesity china52640——−15.1 % vs −1.1 %
estimand not specified
———————press release
48 mg Q2Wobesity china52640——−18.5 % vs −1.1 %
estimand not specified
———————press release

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Verbatim quotes from the source (2)
  • 24 mg Q2W · weight_unsp · press release
    achieved mean body weight reductions of 15.12% and 18.54%, respectively, compared with 1.11% in the placebo group
  • 48 mg Q2W · weight_unsp · press release
    achieved mean body weight reductions of 15.12% and 18.54%, respectively, compared with 1.11% in the placebo group

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: GRADUAL-1 (NCT06728124). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/gradual-1/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.